#United States #Detroit #Clinical Trials #SciTech Development #nanoFenretinide

SciTech Development's Remarkable $5.5 Million Funding Round

In a significant leap forward for cancer therapy, SciTech Development, Inc. has officially announced the closure of its Convertible Note Round #3 (CNR 3), raising an impressive $5.5 million. This funding milestone, reached on September 5, 2025, showcases not just the company’s innovative approach to oncology but also the robust confidence investors have in their clinical advancements. Originally targeting $3 million, the oversubscription of the funding round by an additional $2.5 million highlights the enthusiasm surrounding SciTech's lead drug candidate, ST-001 nanoFenretinide™.

Unprecedented Clinical Outcomes

The extraordinary results from interim clinical trials of ST-001 have played a crucial role in attracting investor interest. In an exhilarating turn of events, the drug has achieved a remarkable 100% disease control rate at higher dose levels, with all participants showing either stable disease or signs of a promising recovery trajectory. Remarkably, confirmed partial responses have been documented in several patients, marking a significant step towards comprehensive recovery. This breakthrough showcases ST-001's efficacy across both early and late-stage cancer patients, greatly underscoring its potential as a versatile therapeutic agent.

Together with its clinical efficacy, ST-001 has demonstrated admirable safety profiles, with most patients reporting minimal side effects. Patients have chosen to stay enrolled in the trials due to the positive impacts on their overall health and quality of life. Earle Holsapple, CEO of SciTech Development, expressed gratitude towards both new and returning investors, emphasizing how their financial confidence underscores the transformative potential of their groundbreaking drug.

Enhancing Future Clinical Development

The substantial funds raised will be pivotal for advancing clinical trials not only for T-cell Non-Hodgkin Lymphoma (T-cell NHL) but also for Small Cell Lung Cancer, as the company aims to build a strong foundation for future developments within its therapeutic pipeline. Andrew Stumpf, CFO of SciTech Development, indicated that investor motivation has been significantly driven by the exceptional interim results and the capabilities of the team behind ST-001.

The proprietary nanotechnology utilized in ST-001’s design holds promise not just for these specific cancers but indicates a potential applicability across a broader spectrum of malignancies, welcoming new hope for effective cancer treatments.

Conclusion

SciTech Development, Inc. is at the forefront of the battle against cancer, utilizing cutting-edge technology to enhance drug delivery for more effective treatment options. As the company moves forward into the next phase of clinical trials, the bright prospects associated with ST-001 could redefine the landscape of cancer therapy for a multitude of patients seeking better outcomes. The current wave of investor support reflects a broader optimism within the field of oncology, promising not only advancements in treatment but also a renewed focus on patient-centric solutions in drug development.

In the coming months, stakeholders will be keenly observing the continued progress of SciTech Development as it strives to translate promising clinical results into tangible therapeutic options for cancer patients worldwide.